Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer

King Faisal Specialist Hospital & Research Center285 enrolled

Overview

Phase II trial of Neoadjuvant \[FEC100\]/Cisplatin-Docetaxel ± Trastuzumab in women with over expressed or amplified Her2/Neu with Locally advanced Breast Cancer

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

285

Conditions

Breast Cancer

Interventions

Cisplatin-Docetaxel ± TrastuzumabRADIATION

Chemo \& RT

Cisplatin-Docetaxel ± TrastuzumabOTHER

Chemo \& RT

Cisplatin-Docetaxel ± TrastuzumabDRUG

Chemo \& RT

Eligibility

Sex: FEMALE

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with locally advanced breast cancer

Outcomes

Primary Outcomes

Efficacy

Time frame: overall

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.